Research programme: leukotriene B4 receptor antagonists - Dong Wha/Procter & Gamble

Drug Profile

Research programme: leukotriene B4 receptor antagonists - Dong Wha/Procter & Gamble

Alternative Names: DW-1352

Latest Information Update: 01 Dec 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong Wha Pharmaceutical
  • Class
  • Mechanism of Action Bone resorption factor inhibitors; Leukotriene B4 receptor antagonists; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 04 Jul 2007 Preclinical development for Osteoporosis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top